205 filings
8-K
ENTA
Enanta Pharmaceuticals Inc
12 Mar 24
Departure of Directors or Certain Officers
4:00pm
EFFECT
ENTA
Enanta Pharmaceuticals Inc
9 Feb 24
Notice of effectiveness
12:15am
10-Q
2024 Q1
ENTA
Enanta Pharmaceuticals Inc
Quarterly report
8 Feb 24
4:24pm
8-K
ENTA
Enanta Pharmaceuticals Inc
7 Feb 24
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
4:05pm
CORRESP
ENTA
Enanta Pharmaceuticals Inc
6 Feb 24
Correspondence with SEC
12:00am
ARS
50h0jf
26 Jan 24
Annual report to shareholders
4:39pm
DEFA14A
6tsosldq0
26 Jan 24
Additional proxy soliciting materials
4:37pm
8-K
twzdu
26 Dec 23
Departure of Directors or Certain Officers
4:06pm
UPLOAD
5k6cjzrv8s
27 Nov 23
Letter from SEC
12:00am
S-3
gte agb9ew
22 Nov 23
Shelf registration
4:38pm
POSASR
hgllvn3vwxf
22 Nov 23
Automatic shelf registration (post-effective amendment)
4:12pm
8-K
ybqde9 ll8al8
20 Nov 23
Results of Operations and Financial Condition
4:05pm
S-8
pbb5x2bhb7df95t23 to
8 Aug 23
Registration of securities for employees
4:23pm
8-K
uyy8x
7 Aug 23
Results of Operations and Financial Condition
4:06pm
8-K
c3n lh7myicfpsfajthj
7 Jun 23
Regulation FD Disclosure
7:01am
8-K
q5wpfb2j2wj
8 May 23
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
4:06pm